Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Malvern Instruments is Premier Sponsor of Inaugural PEGS China

Published: Tuesday, March 25, 2014
Last Updated: Monday, March 24, 2014
Bookmark and Share
Company will present its analytical toolkit for biopharma applications.

Malvern Instruments is premier sponsor of the inaugural PEGS China meeting. The PEGS China Protein & Antibody Engineering and Development summit is presented by Cambridge Healthtech Institute and takes place in Shanghai from 1 - 3 April 2014.

Malvern is participating in both the conference and the associated exhibition, with Dr Wei Qi, Senior Scientist within Malvern’s Bioscience Development Initiative, presenting a paper on ‘Emerging techniques for therapeutic protein characterization - viscosity, stability and sub-visible particles’.

Dr Wei Qi’s presentation is on 1 April, contributing to the ‘Analytical characterization and stability’ conference track, and will explore novel techniques for protein therapeutics characterization. He will describe how, using less than 10 mL sample, it is possible to measure viscosity up to 160 cP contemporaneously with concentration up to 200 mg/mL.

He will also talk about the novel combination of Raman Spectroscopy and Dynamic Light Scattering (DLS) for the simultaneous characterization of protein secondary and tertiary structure, and hydrodynamic size at high concentration. This new technology enables the assessment of conformational and colloidal stabilty under applied stresses, which is extremely useful when comparing different candidate bioformulations.

As part of the associated exhibition, Malvern will present instruments from the company’s rapidly advancing analytical toolkit for biopharmaceutical development. Established solutions, such as Viscotek size exclusion chromatography systems for assessing product purity and the Zetasizer range for sizing and zeta potential analysis for product stability, sit alongside exciting new technologies.

The Viscosizer 200, for example, which is used to assess bioformulation suitability and stability as early as late stage discovery, Archimedes, which uses the technique of resonant mass measurement for counting and measuring sub-micron and sub-visible aggregates and differentiating them from contaminants such as silicone oil in pharmaceutical formulations, and the Nanosight range of Nanoparticle Tracking Analysis instruments to quantify early protein aggregation.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Malvern takes ACHEMA Visitors from R&D Through to Product QC
Visitors to the Malvern Instruments stand at ACHEMA 2012 will see how the company’s range of complementary materials characterization technologies and instrumentation support the needs of manufacturing industry.
Wednesday, March 28, 2012
Malvern Scientists will lead Protein Characterization Workshop at PEGS Summit
Drs Kevin Mattison, Ulf Nobbmann and Jason Sanchez will lead a workshop at the 7th Annual PEGS.
Tuesday, September 13, 2011
Scientific News
Breakthrough Flu Vaccine Inhibited by Pre-existing Antibodies
Universal truths – how existing antibodies are sabotaging the most promising new human flu vaccines.
NIH Begins Yellow Fever Vaccine Trial
NIH has initiated an early-stage clinical trial of a vaccine to protect against yellow fever.
Antibody Drug Shows Promise in HIV Treatment
Researchers are a step closer to an alternative HIV treatment that has the potential for lasting effects and less frequent dosing.
Flu Vaccine May Reduce Risk of Death For Type 2 Diabetes Patients
Researchers at Imperial College London have suggested that the vaccine may have substantial benefits for patients with long-term conditions.
Flu Vaccine May Reduce Death Risk of Type 2 Diabetes
New research suggests that a new flu vaccine may reduce probability of type 2 diabetes patients being hospitalised with stroke and heart failure.
Disrupting Tumour-Promotion in Humans
Researchers have modified an existing protein to represses a specific cancer-promoting ‘message’ within cells.
Protein Nanocages Could Improve Drug Design and Delivery
HHMI scientists have designed and built 10 large protein icosahedra that are similar to viral capsids that carry viral DNA.
Vaccine Strategy Targets Multiple Influenza Viruses
Scientists have identified vaccine-induced antibodies that can neutralize strains of influenza virus that infect humans.
Antibody-Based Drug for Multiple Sclerosis
New antibody-based drug paves the way for new strategies for controlling and treating multiple sclerosis.
Structure of Cold Virus Solved
Researchers have identified the structure of an elusive cold virus linked to child asthma and respiratory infections, providing the foundation for treating the virus.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!